BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 38684437)

  • 1. [Evidence of GVHD/GVL in allogeneic hematopoietic stem cell transplantation from sex-mismatched donors].
    Nakasone H
    Rinsho Ketsueki; 2024; 65(4):265-271. PubMed ID: 38684437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multicenter analyses demonstrate significant clinical effects of minor histocompatibility antigens on GvHD and GvL after HLA-matched related and unrelated hematopoietic stem cell transplantation.
    Spierings E; Kim YH; Hendriks M; Borst E; Sergeant R; Canossi A; Oudshoorn M; Loiseau P; Dolstra H; Markiewicz M; Leffell MS; Pereira N; Kircher B; Turpeinen H; Eliaou JF; Gervais T; Laurin D; Enczmann J; Martinetti M; Thomson J; Oguz F; Santarone S; Partanen J; Siekiera U; Alessandrino EP; Kalayoglu S; Brand R; Goulmy E
    Biol Blood Marrow Transplant; 2013 Aug; 19(8):1244-53. PubMed ID: 23756210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sibling versus unrelated donor allogeneic hematopoietic cell transplantation for chronic myelogenous leukemia: refined HLA matching reveals more graft-versus-host disease but not less relapse.
    Weisdorf DJ; Nelson G; Lee SJ; Haagenson M; Spellman S; Antin JH; Bolwell B; Cahn JY; Cervantes F; Copelan E; Gale R; Gratwohl A; Khoury HJ; McCarthy P; Marks DI; Szer J; Woolfrey A; Cortes-Franco J; Horowitz MM; Arora M;
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1475-8. PubMed ID: 19822308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants.
    Randolph SS; Gooley TA; Warren EH; Appelbaum FR; Riddell SR
    Blood; 2004 Jan; 103(1):347-52. PubMed ID: 12969970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allogeneic HY antibodies detected 3 months after female-to-male HCT predict chronic GVHD and nonrelapse mortality in humans.
    Nakasone H; Tian L; Sahaf B; Kawase T; Schoenrock K; Perloff S; Ryan CE; Paul J; Popli R; Wu F; Otani JM; Coller J; Warren EH; Miklos DB
    Blood; 2015 May; 125(20):3193-201. PubMed ID: 25766725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chromosome Y-encoded antigens associate with acute graft-versus-host disease in sex-mismatched stem cell transplant.
    Wang W; Huang H; Halagan M; Vierra-Green C; Heuer M; Brelsford JE; Haagenson M; Scheuermann RH; Telenti A; Biggs W; Pearson NM; Udell J; Spellman S; Maiers M; Kennedy CJ
    Blood Adv; 2018 Oct; 2(19):2419-2429. PubMed ID: 30262602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role and novel use of natural killer cells in graft-versus-leukemia reactions after allogeneic transplantation.
    Hadjis AD; McCurdy SR
    Front Immunol; 2024; 15():1358668. PubMed ID: 38817602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
    Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
    PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunomonitoring of graft-versus-host minor histocompatibility antigen correlates with graft-versus-host disease and absence of relapse after graft.
    Laurin D; Hannani D; Pernollet M; Moine A; Plumas J; Bensa JC; Cahn JY; Garban F
    Transfusion; 2010 Feb; 50(2):418-28. PubMed ID: 19843288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning.
    Baron F; Lechanteur C; Willems E; Bruck F; Baudoux E; Seidel L; Vanbellinghen JF; Hafraoui K; Lejeune M; Gothot A; Fillet G; Beguin Y
    Biol Blood Marrow Transplant; 2010 Jun; 16(6):838-47. PubMed ID: 20109568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response.
    Jones SC; Murphy GF; Korngold R
    Biol Blood Marrow Transplant; 2003 Apr; 9(4):243-56. PubMed ID: 12720217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-intensity allogeneic hematopoietic stem cell transplantation for myeloid malignancies: separating graft-versus-leukemia effects from graft-versus-host disease.
    Burroughs L; Storb R
    Curr Opin Hematol; 2005 Jan; 12(1):45-54. PubMed ID: 15604891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Graft Cryopreservation Does Not Impact Overall Survival after Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis.
    Hamadani M; Zhang MJ; Tang XY; Fei M; Brunstein C; Chhabra S; D'Souza A; Milano F; Phelan R; Saber W; Shaw BE; Weisdorf D; Devine SM; Horowitz MM
    Biol Blood Marrow Transplant; 2020 Jul; 26(7):1312-1317. PubMed ID: 32283185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dissecting graft-versus-leukemia from graft-versus-host-disease using novel strategies.
    Warren EH; Deeg HJ
    Tissue Antigens; 2013 Apr; 81(4):183-93. PubMed ID: 23510414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Donor Lymphocyte Infusions for Chronic Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation: May We Predict Graft-versus-Leukemia Without Graft-versus-Host Disease?
    Radujkovic A; Guglielmi C; Bergantini S; Iacobelli S; van Biezen A; Milojkovic D; Gratwohl A; Schattenberg AV; Verdonck LF; Niederwieser DW; de Witte T; Kröger N; Olavarria E;
    Biol Blood Marrow Transplant; 2015 Jul; 21(7):1230-6. PubMed ID: 25797175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Daratumumab Prevents Experimental Xenogeneic Graft-Versus-Host Disease by Skewing Proportions of T Cell Functional Subsets and Inhibiting T Cell Activation and Migration.
    Gao Y; Shan W; Gu T; Zhang J; Wu Y; Li X; Zeng X; Zhou H; Chen Z; Xiao H
    Front Immunol; 2021; 12():785774. PubMed ID: 34987512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genome-wide minor histocompatibility matching as related to the risk of graft-versus-host disease.
    Martin PJ; Levine DM; Storer BE; Warren EH; Zheng X; Nelson SC; Smith AG; Mortensen BK; Hansen JA
    Blood; 2017 Feb; 129(6):791-798. PubMed ID: 27872059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ex vivo detection of CD8 T cells specific for H-Y minor histocompatibility antigens in allogeneic hematopoietic stem cell transplant recipients.
    Nakamura R; La Rosa C; Tsai W; Lacey SF; Srivastava T; Seidel A; Senitzer D; Forman SJ; Diamond DJ
    Transpl Immunol; 2014 May; 30(4):128-35. PubMed ID: 24582729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ikaros deficiency in host hematopoietic cells separates GVL from GVHD after experimental allogeneic hematopoietic cell transplantation.
    Toubai T; Guoqing H; Rossi C; Mathewson N; Oravecz-Wilson K; Cummings E; Wu J; Sun Y; Choi S; Reddy P
    Oncoimmunology; 2015 Jul; 4(7):e1016699. PubMed ID: 26140241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.